Move to topTop

TOKYO, JAPAN – January 26, 2023 – Terumo Corporation (TSE: 4543) today announced that it will establish the Sustainability Committee as of April 1, 2023 under the Executive Management Meeting, which is responsible for executing management strategies for the Terumo Group. 

In December 2021, the company implemented the Terumo Group Sustainability Policy and revised the sustainability priorities for the Group, with the goal of promoting sustainability management from a long-term perspective to achieve both a sustainable society and sustainable growth for the Terumo Group.

Under the Group Mission of "Contributing to Society through Healthcare," Terumo positions Creating Social Value (CSV) by “Advancing Healthcare” and “Enhancing Patients’ Quality of Life,” which are Terumo's Purpose, as the most important sustainability priority for the Group. In addition, Terumo has set 6 ESG-related priorities as the foundation of the Group’s CSV activities.

In the 5-Year Growth Strategy “GS26” starting from fiscal year 2022, Terumo established monitoring items and KPIs related to CSV and ESG. The Directors and Executive Officers commit to the items and KPIs, which have been embedded in their performance evaluation and will be reflected in their compensation.

Chaired by the President and CEO, the Sustainability Committee is responsible for monitoring the status of CSV and ESG initiatives as well as reporting them regularly to the Executive Management Meeting and the Board of Directors. The Committee will also investigate external sustainability trends and reflect them in the Group’s policies and plans.

Terumo will continue to contribute to the realization of a sustainable and healthy society by not only providing valuable solutions, but also actively working to solve social and environmental issues surrounding healthcare.


Terumo Report
The Terumo Report is an integrated report that includes information on the strengths of our business, mid-long term growth strategies, priority measures, initiatives and the data related to CSV and ESG.

Terumo Report:
Terumo Report ESG section:

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.